Paul J. Mellett - Dec 6, 2024 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: Chief Fin. & Admin Officer
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Stock symbol: ENTA
Transactions as of: Dec 6, 2024
Transactions value $: -$20,883
Form type: 4
Date filed: 12/10/2024, 04:58 PM
Previous filing: Dec 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Sale	-$20.9K	-2.59K	-2.75%	$8.06	91.7K	Dec 6, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.

Content

Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.